A Study of LY3502970 in Participants With Type 2 Diabetes

Part of paid clinical trials in Hialeah, Florida.

Sponsor
Eli Lilly and Company
Study ID
NCT04426474
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • LY3502970 — DRUG
    Administered orally.
  • Placebo — DRUG
    Administered orally.

Study Details

The main purpose of this study is to learn more about the safety of LY3502970 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3502970 is in the bloodstream, how long it takes the body to eliminate it, and how it affects blood sugar. Participation could last up to 18 weeks and may include up to 14 visits (including three overnight stays) in the study center.

Key Dates

Start date
Oct 8, 2020
Status verified
Apr 2026
Primary completion
Jul 12, 2021
Completion
Jul 12, 2021

Study Design

Enrollment
68 participants (actual)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY3502970
    3, 6, 9, 12, 15, 21, 27, 36 and 45 milligrams (mg) LY3502970 administered orally.
  • Placebo Comparator: Placebo
    Placebo administered orally.

Primary Outcome Measure

Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug [ Time Frame: Baseline through Follow-up (up to Day 105) ]

Locations (4)

FacilityCityStateZIPSite coordinators
Clinical Pharmacology of MiamiHialeahFlorida33014-
Hassman Research InstituteMarltonNew Jersey08053-
Midwest Clinical Research UnitDaytonOhio45417-
Endeavor Clinical TrialsSan AntonioTexas78229-

Related coverage on Hipa.ai

Find similar trials in Hialeah, FL

By condition

Related Studies